Reparixin is under clinical development by Dompe Farmaceutici and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Reparixin’s likelihood of approval (LoA) and phase transition for Pancreatic Islet Transplant Rejection took place on 23 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Reparixin Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Reparixin overview

Reparixin (Repertaxin) is under development to improve the efficacy of transplantation after pancreatic islet B-cell (rare) (allogenic and autologous setting) transplant, HER2 negative metastatic breast cancer, metastatic triple-negative breast cancer, cancer related fatigue in patients with locally advanced or metastatic breast cancer, and liver transplantation, patients with pneumonia associated COVID -19 and acute respiratory distress syndrome. The drug candidate is administered orally as a tablet and through intravenous infusion. Repertaxin targets CXC chemokine receptors CXCR1 and CXCR2. It was also under development for the delayed graft dysfunction after kidney transplantation and primary graft dysfunction after lung transplantation.

Dompe Farmaceutici overview

Dompe Farmaceutici (Dompe) is a developer of therapeutic solutions that research novel therapies for the treatment of rare and orphan diseases. The company offers supplement, cosmetics, medical device, OTC and food products. its products portfolio includes alfa, argonal, rtrosilene, bioritmon, euchlorintima, florberry, memac and sintotrate, among others. The company offers treatment in the therapeutic areas of respiratory diseases, chronic obstructive pulmonary disease, pulmonary arterial hypertension, cystic fibrosis, osteoarticular solutions, pain therapy and dentistry. Dompe’s target research areas comprise respiratory diseases, oncology, diabetology, ophthalmology, organ transplantation, chronic obstructive pulmonary disease and pulmonary arterial hypertension. The company has operations in the US and Albania. Dompe is headquartered in Milan, Italy.

Quick View Reparixin LOA Data

Report Segments
  • Innovator
Drug Name
  • Reparixin
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Immunology
  • Infectious Disease
  • Oncology
  • Respiratory
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.